Home » Newsletters » BioWorld Science

BioWorld Science

June 24, 1999

View Archived Issues

Synsorb Biotech licenses potential cystic fibrosis therapies

MiniMed enters collaboration with Elan for Medipad drug delivery system

Copley launches first controlled drug

Company Profile: Probiodrug

Cell Pathways completes phase III APC trial analysis

Amarillo Biosciences reaches IFN-alpha development agreement in China

Two gene therapy clinical trials under way for coronary artery disease

PowderJect and Glaxo Wellcome further expand DNA vaccine alliance

FDA approves new glucose monitoring system

Solvay announces commencement of tender offer to acquire Unimed

Gliatech presents results of new antiinflammation program

Immune Response implements restructuring plan

Avant receives approval to conduct clinical trial of atherosclerosis vaccine

CLX-0901: a novel compound for the treatment of type II diabetes

Calyx scientists identify CLX-0301, a novel antidiabetic and candidate for clinical testing

Takeda presents new compounds for asthma, allergic disorders

Ion and collaborators focus efforts on sickle cell disease and proliferative disorders

Erythromycin derivatives prepared under Taisho-Sagami collaboration

AM-6898E: new anti-IgE antibody agent for immune disorders

Does melatonin improve the tolerability of chemotherapy?

Antidiabetic activity and mechanism of action of R-102380, a novel TZD from Sankyo

Early indications of antidiabetic potential for adenosine A1 agonist from Glaxo Wellcome

Potential new use for donepezil: Rx of dyskinesias and other symptoms in IPD

CRF1 receptor antagonist may be beneficial in stress-induced psychosomatic disorders

GlycoDesign expands GD0039 phase II cancer trial to additional site

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 26, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 27, 2026.
Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease
BioWorld Science
Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...
Muted and missing M&As: JPM deals absent in 2026
BioWorld
For years, the J.P. Morgan Healthcare Conference (JPM) kicked off with splashy headlines of major M&A activity among biopharma companies, but in 2026, the hype...
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...